About Rybelsus®
Class: Oral semaglutide for T2D
Brand/Manufacturer: Novo Nordisk
Dosing: Daily oral (3-14 mg)
Mean weight loss: See PIONEER
Pivotal trial: PIONEER-1 through PIONEER-7
Rybelsus® is Novo Nordisk's oral semaglutide approved for type 2 diabetes. First and only oral GLP-1 RA. Lower bioavailability requires fasting administration. Retail $935/month. Less effective for weight loss than injectable semaglutide.
Mechanism of action
Rybelsus® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is See PIONEER body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Rybelsus®'s weight management indication is PIONEER-1 through PIONEER-7. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Rybelsus® via telehealth
Rybelsus® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Rybelsus® access — see the side panel for details.
FAQ
Is Rybelsus® FDA-approved?
The brand-name versions of Rybelsus® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Rybelsus® cost?
Brand-name Rybelsus® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.